Physicians' Academy for Cardiovascular Education

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients

3' education - Oct. 21, 2019 - Prof. Freek Verheugt, Amsterdam - ESC 2019, Paris

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris

What is mendelian randomization?

5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard

A life course perspective on benefits of lower cholesterol

5' education - Oct. 9, 2019 - ESC 2019, Paris, France - George Thanassoulis

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI

3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris

Potent and durable LDL-c lowering up to 18 months with siRNA against PCSK9

News - Nov. 16, 2019

AHA 2019 The ORION-10 data showed LDL-c lowering of over 50% with inclisiran, which inhibitors production of PCSK9 through RNA interference, with a safety profile similar to placebo.

SGLT2i gives consistent CV benefit in HFrEF patients with or without T2DM

News - Nov. 16, 2019

AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.

Generic anti-inflammatory drug lowers ischemic events in patients with recent MI

News - Nov. 16, 2019

AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.

AHA launches anti-e-cigarette campaign with hashtag #QuitLying addressed to ‘Big Vape’

News - Nov. 16, 2019

AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.

Thiazide or thiazide-like diuretics superior to ACEi as initial monotherapy in hypertension

Literature - Nov. 12, 2019 - Suchard MA, et al. - The Lancet 2019

A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.

Women more likely to develop acute HF with higher mortality risk after STEMI than men

Literature - Nov. 11, 2019 - Cenko E et al. - J Am Coll Cardiol. 2019

This observational study showed that women had a higher risk to develop acute HF after STEMI and women with acute HF after STEMI had a higher mortality rate compared to men.

E-cigarettes not a harm-free alternative to tobacco smoke, suggests critical review of current data

Literature - Nov. 7, 2019 - Buchanan ND et al., - Cardiovasc Res 2019

This review comprehensively summarizes both preclinical and clinical data on the CV effects of e-cigarette use. CV effects of e-cigarette constituents as well as of e-cigarette exposure are reviewed. With poll

Rate, trends and predictors of early mortality after AF ablation

Literature - Nov. 7, 2019 - Cheng EP, et al. - J Am Coll Cardiol 2019

In a real-world cohort including data of >60,000 AF ablation procedures performed between 2010-2015, early mortality rate was 0.46%. Strongest predictors for early mortality were procedural complications, CHF and low AF ablation hospital volume.

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

A study of real-world data of 4 large European primary care databases demonstrates that NAFLD is not associated with increased risk of AMI and stroke, after correction for traditional risk factors.

Decrease in eGFR associated with future risk of renal and CV events in patients with T2DM

Literature - Nov. 4, 2019 - Oshima M et al., - Diabetologia 2019

A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.

Hypertension medication ingestion at bedtime improves asleep ABP and reduces CVD risk

Literature - Oct. 31, 2019 - Hermida RC et al., - Eur Heart J 2019

A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.

Identification of parameters associated with plaque erosion in STEMI and NSTE-ACS

Literature - Oct. 30, 2019 - Yamamoto E et al., - J Am Heart Assoc. 2019

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.